In the rapidly evolving landscape of biochemical research, few topics have generated as much intrigue as the Elabela peptide. Often referred to in scientific literature by various aliases such as Apela or Toddler, this molecule has fundamentally changed our understanding of signaling pathways. As someone deeply interested in the mechanics of cellular biology and peptide science, I have spent considerable time analyzing the data surrounding this fascinating hormonal peptide.
Understanding Elabela Peptide: The Basics
At its core, Elabela (often abbreviated as ELA) is recognized as the second endogenous ligand for the Apelin receptor. While the Apelin system has been studied for years, the discovery of Elabela provided a missing piece to a complex puzzle. It is a peptide that functions as a signaling molecule, effectively acting as a body-own peptide hormone class that modulates various physiological responses.
When we look at Elabela (ELA) in the Elabela(19-32) | Gαi1/β-arrestin-2 Activator context of the APLNR gene and the broader apelinergic system, it becomes clear why researchers are so captivated. Apelin and Elabela are endogenous peptide ligands that interact with the APJ receptor—a G protein-coupled receptor (GPCR) that is widely expressed across different tissues. Because it is a hormone p Elabela eptide belonging to the adipokine group, its influence extends far beyond a single organ system.
Key Structural Variations and Research Fragments
For those looking into specific laboratory applications, the structural diversity of this molecule is significant. One of the most common forms discussed in literature is ELA-32 (human). This is a potent, high-affinity agonist for the apelin receptor, with specific binding constants (IC50 = 0.27 nM; Kd = 0.51 nM) that highlight its biological activity.
Beyond the full-length hormone, researchers frequently utilize shorter, active segments. For instance, Elabela(19-32) is an active fragment of the par by YR Liu·2023·Cited by 10—ELABELA(ELA), also known as Toddler or Apela, is a novel endogenous ligand of the angiotensin receptor AT1-related receptor protein (APJ). ent molecule. ELA(19-32), also known as Elabela(19-32) TFA, is frequently studied for its ability to activate specific pathways, such as Gαi1 and β-arrestin-2 signaling. These fragments are essential for mapping out how elabela regulates cardiac and vascular function in adults, providing insights into how these signals are transduced at the cellu ELABELA (ELA, Apela, Toddler) is ahormonal peptidethat in humans is encoded by the APELA gene. Elabela is one of two endogenous ligands for the G-protein- Read more lar level.
Physiological Significance and Emerging Research
The discovery of Elabela has provided a new lens through which we view systemic homeostasis. It was originally identified as a critical cardiac development by B Liet·2021·Cited by 19—Elabela is a new player in tumor progression and cancer invasion. Elabela is a proangiogenic peptide and can mediate pro-tumorigenic and anti-tumorigenic Read more al peptide, playing a vital role in the early stages of heart and vascular formation in embryonic models.
Recent studies have expanded this scope significantly:
* Neuroprotective Potential: Some research indicates that ELA could alleviate neuronal apoptosis and axonal damage by influencing specific signaling pathways like CTDSP1/AKT.
* Diagnostic Markers: There is growing interest in how ELA can be used as a diagnostic marker for CVDs, given its role in reducing oxidative stress and tissue fibrosis.
* Oncology and Growth: Elabela is a new player in by P Yan·2025—ELA can be used as a diagnostic marker for CVDsand has been demonstrated to reduce oxidative stress, cell apoptosis, tissue fibrosis, and Read more tumor progression and cancer invasion, acting as a proangiogenic molecule that warrants further investigation into its complex, dual-natured effects on cell proliferation.
W ELA-32 (human) | CAS 1680205-79-1 | Apela | Elabela hy the Apelinergic System Matters
The APJR agonist act Elabela Peptide: A New Player in Hypertension and Vascular ivity associated with ELABELA is not merely academic. Because it is a recently discovered hormone, the scientific community is still mapping the full breadth of its reach. Unlike older, more established peptides, ELABELA offers a unique, nuanced approach to understanding how our bodies maintain fluid balance and vascular tone.
Whether examining the full-length ELA peptide or derivatives like Elabela(19-32), the data consistently points toward a highly specialized mechanism of action. It is this specificity—the ability to act as an endogenous peptide ligand that fine-tunes receptor activity without the broad-spectrum effects of other hormones—that makes it a standout subject in modern biochemical studies.
Final Reflections
My interest in Elabela stems from the sheer elegance of its discovery. From its humble beginnings as a "toddler" gene product essential for heart development to its current status as a molecule with potential diagnostic utility for cardiovascular health, the story of this peptide is far from over. As we continue to uncover how elabela peptide interacts with the APLNR gene and other receptors, we gain a clearer picture of the intricate, microscopic highwa 10 a novel peptide elabela is associated with hypertension ys that keep our biological systems in balance. For those of us tracking these developments, the future of this hormonal peptide remains one of the most compelling frontiers in peptide science.